INSM
Wall Street still likes the setup
Roth Mkm basically hit the “same vibe, new reminder” button on Insmed, reaffirming a Buy rating and hanging a $212 price target on the name. That’s not exactly a fireworks moment, but it does tell you the Street still sees upside in the biotech story.
The analyst crowd is still mostly on team INSM
The article says the consensus target is hovering around $213.23, with most firms still rating the stock a Buy. In other words, this isn’t one of those lonely contrarian calls from a single analyst shouting into the void. The herd is still, at least for now, wearing the same jersey.
But there’s a little chop in the water
Not everything in the piece is sunshine and espresso. It also notes that insiders have been net sellers over the last three months, while big holders like Vanguard, State Street and Darwin still keep sizeable stakes. So you’ve got the classic market tug-of-war: analysts saying “upside,” insiders trimming, institutions staying put.
Big picture
For investors, the takeaway is simple: Insmed remains a name with plenty of Wall Street support, which can help keep sentiment warm. But between shifting price targets and insider selling, this is still a stock where conviction is being tested in real time rather than handed to you on a silver platter.